Neuroblox

Neuroblox occupies a specialized position at the intersection of computational neuroscience, neurotechnology, therapeutics, and clinical research. Its differentiation is the use of mechanistic, multiscale circuit models intended to connect interventions with downstream clinical outcomes, rather than relying solely on statistical prediction or generic machine-learning workflows. The platform is designed to simulate drugs, devices, and combination therapies across biological scales, with models informed by more than 1,000 curated studies and validation inputs including non-human-primate electrophysiology and human ultra-high-field fMRI. It also emphasizes patient-specific and population-level modeling, which could support translational research and therapeutic decision-making. Neuroblox appears earlier-stage than established clinical-trial software providers, with one recorded seed round and an employee range of 11–50. Its principal market risk is translating sophisticated simulations into validated, repeatable workflows adopted by biotech and clinical teams.

Neuroblox’s trajectory shows an early transition from scientific research capability toward a venture-backed neurotherapeutics software company. The company is recorded as founded on Jul 1, 2025, creating a chronology concern because the financing date predates the listed founding date; this may reflect incorporation, restructuring, or inconsistent historical dating. Leadership is concentrated among three co-founders: Lilianne Mujica-Parodi became CEO in July 2025, while Helmut Strey and Earl Miller are also listed as co-founders. The product concept combines mechanistic brain-circuit models, automated generative circuit assembly, high-performance computing, AI, and neuroimaging inputs including 7T fMRI, MRS, MEG, and fNIRS. The reported employee band of 11–50 and active careers page indicate continued team-building, but there is insufficient public evidence to quantify headcount growth, customer traction, revenue, additional funding, or product commercialization.